Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$92.37 USD
-0.97 (-1.04%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $92.38 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$92.37 USD
-0.97 (-1.04%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $92.38 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Zacks News
Is Applied Molecular Transport (AMTI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Applied Molecular Transport Inc. (AMTI) and Edwards Lifesciences (EW) have performed compared to their sector so far this year.
Centene (CNC) Q4 Earnings Miss on High Costs, '23 Premium View Up
by Zacks Equity Research
Centene's (CNC) fourth-quarter results suffer from elevated medical expenses, partly offset by growing premium and service revenues.
Edwards Lifesciences (EW) Q4 Earnings Top, Margins Increase
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT, led by the continued adoption of the PASCAL platform in Europe.
Edwards Lifesciences (EW) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2022, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Edwards Lifesciences (EW) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 4.92% and 1.28%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
HOLX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Gains From Innovation Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) continues to witness strong momentum of the RESILIA portfolio globally.
Here's How Much You'd Have If You Invested $1000 in Edwards Lifesciences a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?
by Zacks Equity Research
Strong adoption of the MITRIS RESILIA valve and increased demand for the HemoSphere monitoring platform will likely drive Edwards Lifesciences' (EW) Q4 revenues.
HOLX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HOLX vs. EW: Which Stock Is the Better Value Option?
Here's Why You Should Retain Edwards Lifesciences (EW) Now
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW), led by strong underlying growth across all product groups.
Edwards Lifesciences (EW) Rides on Innovation Amid Rising Costs
by Zacks Equity Research
Edwards Lifesciences (EW) expects to report underlying sales growth in the mid-single-digit range for 2022, banking on market growth and the adoption of premium technologies.
Implied Volatility Surging for Edwards Lifesciences (EW) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Edwards Lifesciences (EW) stock based on the movements in the options market lately.
Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.
Edwards Lifesciences (EW) Lags Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of -1.61% and 1.32%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Integer (ITGR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) to Report Q3 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intuitive Surgical, Inc. (ISRG) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Intuitive Surgical, Inc. (ISRG) delivered earnings and revenue surprises of 8.18% and 2.17%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
What's in Store for Edwards Lifesciences (EW) in Q3 Earnings?
by Zacks Equity Research
Within the TAVR arm, Edwards Lifesciences (EW) is likely to have witnessed continued growth in procedures across the United States and worldwide.
Edwards Lifesciences (EW) TAVR Sales Strong Amid Macro Issues
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales growth in the mid-single-digit range on the back of strength in demand for products used in more intense surgeries.
Edwards Lifesciences (EW) Debuts SAPIEN 3 Ultra RESILIA Valve
by Zacks Equity Research
Edwards Lifesciences' (EW) SAPIEN 3 Ultra RESILIA valve combines its breakthrough RESILIA tissue technology with the SAPIEN 3 Ultra transcatheter aortic heart valve.
Edward Lifesciences (EW) Gains From New Products Amid Cost Woe
by Zacks Equity Research
Edwards Lifesciences (EW) expects full-year 2022 underlying sales to grow on the back of strength in demand for products used in more intense surgeries.
OCPNY or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
OCPNY vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Gets CE Mark for PASCAL Precision
by Zacks Equity Research
Edwards Lifesciences' (EW) PASCAL Precision system enables precise navigation and implant delivery during mitral and tricuspid regurgitation treatment.